Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Marat Gordiev

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

M. Gordiev1, L.H. Shigapova2, O. Brovkina3, R.F. Enikeev4, M. Druzhkov4, A. Nikitin5, E. Shagimardanova2, O. Gusev2

Author affiliations

  • 1 Molecular-diagnostic Laboratoty, Tatarstan Cancer Center, 420029 - Kazan/RU
  • 2 Institute Of Fundamental Medicine And Biology, Kazan Volga Region Federal University, 420008 - Kazan/RU
  • 3 Genetic Laboratory, Federal Research and Clinical Center, FMBA of Russia, 115682 - Moscow/RU
  • 4 Chemoterapy Department, Kazan Clinical Oncology Center, 420029 - Kazan/RU
  • 5 Genetic Laboratoty, Federal Research and Clinical Center, FMBA, 495 - Moscow/RU
More

Resources

Abstract 4963

Background

Lynch syndrome is a hereditary disease caused by mutations in DNA mismatch repair system (MMR), which includes ML1, MS2, MS6, PMS2, EPCAM genes. Clinical manifestation of the Lynch syndrome is usually colorectal cancer (CRC), endometrial cancer, ureteral cancer and kidney cancer. We aimed to analyze occurrence of mutations in MMR system genes in patients with hereditary breast and ovarian cancer.

Methods

We have analyzed 228 samples of blood from patients with hereditary breast (BC) and ovarian cancer (OC) in Tatarstan Regional Clinical Cancer Center, Russia. The criteria for inclusion was at least one out of three observations: Young age of manifestation of breast or ovarian cancer (before 50 y.o. for BC and 55 y.o. for OC), first or second-degree relatives with breast or ovarian cancer, primary-multiple BC and OC. The libraries for sequencing were prepared using NimblGen SepCapEZ Choice (Roche) with custom gene panel followed by sequencing on MiSeq platform.

Results

Eight out of 101 (8%) patients with hereditary OC and five out of 127 (4%) patients with hereditary BC carried pathogenic mutation in one of MMR genes. Average age of manifestation of BC and OC in the patients with Lynch syndrome was 54 y.o. in case of OC and 56 y.o. in case of BC group: 50 y.o. Nine women had first and second-degree relatives with either BC, OC, colon or esophagus cancer. The distribution of affected genes in HBOC cohort was as follows: 3 patients with mutation in MSH6 gene, 4 patients with mutation in PMS2 gene, 2 patients with mutation in MSH2 gene, 3 patients with mutation in mlH1 gene. One patient carried mutation in EPCAM gene.

Conclusions

To date, the clinical standard for screening for Lynch syndrome is the Amsterdam criteria II, which are not oriented to the occurrence of OC and BC in patients, as well as to the presence of these cancers in a hereditary history in patients with colorectal cancer. However, our experience shows that patients with signs of hereditary OC and BC also can be carriers of mutations in the genes of the MMR system, which determine the Lynch syndrome. Thus, impact of Lynch syndrome-associated germline mutation on other types of cancer should be reconsidered and studied in detail.

Clinical trial identification

Legal entity responsible for the study

Tatarstan Cancer Center.

Funding

The work is supported by the Russian Foundation for Basic Research № 18-415-160009 r_a and according to the Russian Government Program of Competitive Growth of Kazan Federal University.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings